Effect of dietary phosphorus restriction on serum fibroblast growth factor 23 (FGF23) levels in patients with chronic kidney disease

Effect of dietary phosphorus restriction on serum fibroblast growth factor 23 (FGF23) levels in patients with chronic kidney disease - Effect of dietary phosphorus restriction on serum FGF23 levels

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003049

Enrollment

Registered

2010-03-01

Start date

2010-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic kidney disease

Interventions

High phosphorus diet for two days. After the period, Low phosphorus diet for five days.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inpatients with chronic kidney disease

Exclusion criteria

Exclusion criteria: 1, Patients with appetite loss 2, Patients taking vitamin D 3, Patients with rapidly deteriorated renal function 4, Patients who do not agree with participation in this study 5, Patients who are inappropriate for study inclusion

Design outcomes

Primary

Measure	Time frame
Difference of change in serum FGF23 levels before and after dietary phosphorus restriction between CKD stage 1,2 and stage 4,5	—

Secondary

Measure	Time frame
Effect of serum phosphate, parathyroid hormone, 1,25D, daily phosphate excretion, and daily protein intake on change of serum FGF23 levels	—

Countries

Japan

Contacts

Public ContactShunsuke Goto

Kobe University Graduate School of Medicine Division of Nephrology and Kidney Center

sgoto@med.kobe-u.ac.jp078-382-6500

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026